Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 11, 2018* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL
-
Nov 8, 2018Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m., ET
-
Nov 7, 2018* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)
-
Oct 23, 2018- Top-line data from the "PULSE" clinical trial expected in the second quarter of 2019
-
Oct 19, 2018-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
-
Oct 16, 2018- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery